# Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects

> **NCT02992418** · PHASE3 · TERMINATED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 688 (actual)

## Conditions studied

- Dengue Fever
- Dengue Hemorrhagic Fever

## Interventions

- **BIOLOGICAL:** CYD Dengue Vaccine
- **BIOLOGICAL:** Tdap: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine adsorbed
- **BIOLOGICAL:** Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed

## Key facts

- **NCT ID:** NCT02992418
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-12-19
- **Primary completion:** 2019-12-10
- **Final completion:** 2019-12-10
- **Target enrollment:** 688 (ACTUAL)
- **Why stopped:** No answer received from the Philippines Food and Drug Administration on protocol amendment issued due to IDMC recommendations. CYD vaccine 3rd dose not given.
- **Last updated:** 2022-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02992418

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02992418, "Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02992418. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*